You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Orally active, potent and competitive HMG-CoA reductase inhibitor (IC50 = 40 -100 nM at human liver microsomes). Inhibits vascular smooth muscle proliferation in vitro (IC50 = 70 nM) and exhibits antihypercholesterolemic and antioxidant activity in vivo.
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 433.45. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.31 mL||11.54 mL||23.07 mL|
|5 mM||0.46 mL||2.31 mL||4.61 mL|
|10 mM||0.23 mL||1.15 mL||2.31 mL|
|50 mM||0.05 mL||0.23 mL||0.46 mL|
References are publications that support the biological activity of the product.
Dansette et al (2000) HMG-CoA reductase activity in human liver microsomes: comparative inhibition by STAT. Exp.Toxicol.Pathol. 52 145 PMID: 10965989
Yamamoto et al (2001) Antioxidative effects of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on peroxidation of phospholipid liposomes. J.Pharm.Pharmacol. 53 227 PMID: 11273020
Turner et al (2007) Comparison of the efficacies of five different STAT on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J.Cardiovasc.Pharmacol. 50 458 PMID: 18049315
If you know of a relevant reference for Fluvastatin sodium, please let us know.
View Related Products by Product Action
Keywords: Fluvastatin sodium, Fluvastatin sodium supplier, HMG-CoA, reductases, inhibitors, inhibits, statins, Reductase, 3309, Tocris Bioscience
5 Citations for Fluvastatin sodium
Citations are publications that use Tocris products. Selected citations for Fluvastatin sodium include:
Li and Fountain (2012) Fluvastatin suppresses native and recombinant human P2X4 receptor function. Purinergic Signal 8 311 PMID: 22222818
Bergman et al (2011) Studies on the antibacterial effects of STAT--in vitro and in vivo. PLoS One 6 e24394 PMID: 21912631
Vainio et al (2011) Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by STAT. Am J Physiol Renal Physiol 2 1176 PMID: 22202492
Rojo-Arreola et al (2014) Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis. PLoS One 9 e87594 PMID: 24489942
Park et al (2016) Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol 17 914 PMID: 27270401
Do you know of a great paper that uses Fluvastatin sodium from Tocris? Please let us know.
Reviews for Fluvastatin sodium
There are currently no reviews for this product. Be the first to review Fluvastatin sodium and earn rewards!
Have you used Fluvastatin sodium?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.